Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced